New case series sharpens the picture on ocular FIP treatment

CURRENT FULL VERSION: A new observational case series offers one of the clearest looks yet at antiviral treatment for ocular FIP, a form of feline infectious peritonitis that can present with anterior or posterior uveitis, iris color change, retinal lesions, and vision-threatening complications. In the 2025 Journal of Veterinary Internal Medicine report, 20 cats with ocular involvement were treated with remdesivir, GS-441524, or both; all started an 84-day treatment course, 80% survived, and among 11 cats with uveitis and long-term follow-up, nine had resolution of uveitis. The authors concluded that FIP-associated uveitis responded effectively in most cases, though some cats were left with persistent sequelae such as secondary glaucoma. (pubmed.ncbi.nlm.nih.gov)

The timing matters. FIP has shifted from a near-uniform fatal diagnosis to a treatable disease in many cases, driven by growing evidence for nucleoside analog antivirals including GS-441524 and remdesivir. U.S. practice changed materially on May 10, 2024, when FDA said it did not intend to enforce new animal drug approval requirements for veterinarian-prescribed, patient-specific compounded GS-441524 for cats with FIP under the conditions in Guidance for Industry #256, while also emphasizing that compounded products from bulk substances are still unapproved and “not, in fact, legal.” Shortly after, Cornell’s Feline Health Center highlighted the launch of a compounded oral GS-441524 product in the U.S., a step that moved treatment from informal sourcing toward mainstream veterinary oversight. (fda.gov)

Against that backdrop, the ocular case series helps answer a question many clinicians have faced in referral and general practice: what happens to the eye lesions once antiviral therapy starts? According to the abstract, 17 of the 20 cats initially received remdesivir, and 70% of those cats were started at 15 to 20 mg/kg/day. Thirteen of 15 cats with anterior uveitis also received topical anti-inflammatory medication, suggesting that local ophthalmic management remained an important adjunct rather than antiviral therapy acting alone. The paper’s figures describe visible improvement in iris color change after just three days of remdesivir in one cat, but the overall message is more measured: most improved, some required long-term management, and not every lesion fully resolved. That practical framing matters because ocular FIP is often tied to the non-effusive form of disease, can occasionally be the dominant presenting feature, and may show a wide range of findings, from keratic precipitates, dyscoria, hyphema, and fibrinous exudate in the anterior chamber to retinal hemorrhage, vascular tortuosity, gray-white fundic lesions, or retinal detachment posteriorly. (pubmed.ncbi.nlm.nih.gov)

That fits with the broader literature. Earlier studies had already shown promising outcomes for remdesivir and GS-441524 in FIP, including protocols that used higher doses for ocular or neurologic disease. A 2023 JVIM study of 32 cats treated with remdesivir and GS-441524 noted that cats with neurologic or ocular FIP were started at 15 to 20 mg/kg once daily. More recent analyses, including a 2025 Scientific Reports paper covering cats treated from 2020 to 2024, found strong outcomes even in ocular and neurologic cases when dosing was sufficient, but also warned that some CNS or ocular damage may not be reversible. That study explicitly argues for starting treatment before injury becomes permanent. Separately, newer clinical discussion around dosing and duration has emphasized that early improvement can be misleading: many cats eat better, gain weight, and look markedly improved within the first week, but that does not necessarily mean viral clearance. Investigators are increasingly looking at more objective treatment-stop criteria, including trends in serum amyloid A, alpha-1 acid glycoprotein, and the albumin:globulin ratio, especially in cases involving harder-to-penetrate tissues such as the eye and central nervous system. (academic.oup.com)

Guideline and expert context also supports why this matters clinically. The 2025 ABCD FIP guideline says FIP is a notable cause of feline uveitis and details the range of ocular manifestations clinicians may see, from anterior uveitis and aqueous flare to chorioretinitis, retinal vasculitis, and retinal detachment. Those signs overlap with toxoplasmosis, lymphoma, FIV, and FeLV, so diagnosis still depends on the full clinical picture rather than the eye exam alone. Broader clinical updates also reinforce that FIP remains a presumptive diagnosis in many real-world cases, built from signalment, history, clinicopathologic patterns, imaging, effusion analysis when present, and compatible ocular or neurologic findings rather than a single definitive test available in every practice. For veterinarians, the practical takeaway is that ocular disease may be one of the most visible clues to systemic FIP, but it also signals a case that may need more aggressive antiviral dosing and closer monitoring. (abcdcatsvets.org)

Why it matters: For veterinary teams, this is less about a brand-new drug than about better case selection, dose planning, and client communication. Ocular FIP can now be discussed with more realism: many cats improve, many survive, and uveitis often resolves, but treatment may still require high-dose protocols, topical ophthalmic support, serial rechecks, and honest conversations about residual deficits. The newer literature also reinforces a point that practices are learning in real time: weight gain during recovery, evolving clinical signs, and late-emerging neurologic or ocular findings can all affect dose adjustments and duration. In other words, these are not “set it and forget it” cases. (pubmed.ncbi.nlm.nih.gov)

There’s also a quality and compliance angle. Before U.S. access improved, many pet parents turned to unregulated sources, and published research has shown that unlicensed antiviral products used at home can contain amounts of GS-441524 that differ significantly from what’s advertised. That history helps explain why veterinarians may increasingly favor documented, pharmacy-compounded pathways and more standardized monitoring as treatment becomes normalized in practice. (pubmed.ncbi.nlm.nih.gov)

What to watch: The next phase is likely to focus on standardizing dosing for ocular and neuro-ocular cases, defining when treatment should extend beyond 84 days, and clarifying which ocular changes predict permanent visual impairment versus reversible inflammation. As more U.S. clinicians gain hands-on experience with compounded GS-441524 under FDA’s current enforcement posture, expect more real-world outcome data, and possibly sharper consensus on how to manage relapse, persistent ocular sequelae, combination therapy, and objective treatment-stop criteria rather than relying on clinical improvement alone. (fda.gov)